Clinical trials: FIGO Stage III Ovarian Cancer
Fallopian Tube Cancer, Metastatic Cancer
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00993655
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 50 sites in United States, Canada and 2 more
- Volunteers
- 275 people
- Sponsor
- Canadian Cancer Trials Group
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
This phase II trial determines if giving goserelin acetate injections in the upper gluteal region is as effective for ovarian function suppression (OFS) as giving injections in the abdomen for ovarian function suppression (OFS)…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Hormone Receptor-Positive Breast Carcinoma
- Trial name
- NCT07460752
- Testing
- Biospecimen Collection, Goserelin Acetate, Questionnaire Administration
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Mayo Clinic
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer
RATIONALE: Measuring the amount of prostaglandin metabolite in urine samples and studying tissue samples in the laboratory from patients with ovarian cancer may help doctors identify and learn more about biomarkers related to…
- Trial name
- NCT00900523
- Testing
- protein expression analysis, immunohistochemistry
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Adult Solid Neoplasm, Recurrent Ovarian Carcinoma
Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery
This phase I trial is studying the side effects and best dose of eribulin mesylate and gemcitabine hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Adult Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Ovarian Cancer AJCC v6 and v7
- Trial name
- NCT00410553
- Testing
- Eribulin Mesylate, Gemcitabine Hydrochloride
- Where
- 2 sites in Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer, Kidney Cancer
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in…
- Conditions
- Endometrial Cancer, Kidney Cancer, Ovarian Cancer, Pheochromocytoma
- Trial name
- NCT00002641
- Testing
- filgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 45 sites in Austria, Belgium and 11 more
- Volunteers
- 350 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Childhood Germ Cell Tumor, Ovarian Cancer
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
RATIONALE: Germ cell tumors (GCT) are highly sensitive to chemotherapy such that even with metastatic disease at diagnosis, many patients can be cured.
- Conditions
- Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00432094
- Testing
- carboplatin, etoposide, ifosfamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot Early Phase I clinical trial studies epacadostat before surgery in treating patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7
- Trial name
- NCT02042430
- Testing
- Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00138242
- Testing
- carboplatin, docetaxel, adjuvant therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Ovarian Cancer
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- ETC (NCT00005612)
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination
This trial is a randomized, open-label Phase I-2 multi-center study designed to evaluate the effect of Carboplatin-Paclitaxel-Bevacizumab (in combination and maintenance) vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib (Rucaparib…
- Trial name
- MITO25 (NCT03462212)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 7 sites in Italy
- Volunteers
- 290 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cancer
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who…
- Trial name
- NCT00949052
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT01074398
- Testing
- gene expression analysis, polymorphism analysis, protein expression analysis
- Volunteers
- 513 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Endometrial Cancer, Fallopian Tube Cancer
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003560
- Testing
- carboplatin, docetaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc